The Illinois Comprehensive Cancer Center (ICC) is a confederation of four specialized Cancer Centers in Chicago and other health institutions and organizations in Illinois. Twelve medical schools, the School of Public Health, the Illinois Institute of Technology, the department of Public Health of Chicago and the State Medical Society and Hospital Association are active participants in the project. During the first 18 months of Core support of this Center, the role of the Center significantly broadened. Meritorious programs within individual institutions have been fostered by the Center as potential models for future consortial activity. Also the principle of multi-institutional programming has been found at times less desirable, if this approach required compromising the quality of the endeavors. Thus, although network-type paradigms remain the goal, single institution projects are forming an important activity of the Center. The functions of the two funded specialized Centers in Chicago (Northwestern and the University of Chicago) have been more closely integrated with the ICC. ICC is also becoming the major means for creating a centralized resource for regional programs in clinical research, basic research, epidemiology and cancer control. The ICC Division of Research Resources, for example provides centralized support in the areas of Computer Services and Biostatistics for all programs of the Center. The Computer Services operation has designed a data base management system which controls and coordinates all applications of the consortial data base, while Biostatistics staff has concentrated in three broad areas of consultation: clinical research, evaluation and cancer control.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA021742-10
Application #
3101636
Study Section
(SRC)
Project Start
1978-12-01
Project End
1992-11-30
Budget Start
1987-12-04
Budget End
1988-11-30
Support Year
10
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Illinois Cancer Center
Department
Type
DUNS #
City
Chicago
State
IL
Country
United States
Zip Code
60604
Kucuk, O; Kilton, L; Wade, J L et al. (2000) Phase II trial of menogaril in patients with previously treated multiple myeloma or chronic lymphocytic leukemia. Am J Clin Oncol 23:379-83
Rosen, F; Vokes, E E; Lad, T et al. (1995) Phase II study of amonafide in the treatment of patients with advanced squamous cell carcinoma of the head and the neck. An Illinois Cancer Center study. Invest New Drugs 13:249-52
Shevrin, D H; Lad, T E; Guinan, P et al. (1994) Phase II trial of echinomycin in advanced hormone-resistant prostate cancer. An Illinois Cancer Council study. Invest New Drugs 12:65-6
Kies, M S; Grinblatt, D; Runge-Morris, M et al. (1994) Phase II study of intravenous melphalan (NSC-8806) in the treatment of patients with advanced squamous carcinoma of the head and neck. Invest New Drugs 12:45-7
Kilton, L J; Ashenhurst, J B; Wade 3rd, J L et al. (1994) Phase II study of fludarabine phosphate for gastric adenocarcinoma. An Illinois Cancer Center trial. Invest New Drugs 12:163-6
Giovanazzi-Bannon, S; Rademaker, A; Lai, G et al. (1994) Treatment tolerance of elderly cancer patients entered onto phase II clinical trials: an Illinois Cancer Center study. J Clin Oncol 12:2447-52
Locker, G Y; Kilton, L; Khandekar, J D et al. (1994) High-dose aminothiadiazole in advanced colorectal cancer. An Illinois Cancer Center phase II trial. Invest New Drugs 12:299-301
Shevrin, D H; Kilton, L J; Lad, T E et al. (1994) Phase II trial of 6-thioguanine in advanced renal cell carcinoma. An Illinois Cancer Center study. Invest New Drugs 12:345-6
Kuzel, T M; Tallman, M S; Shevrin, D et al. (1993) A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. An Illinois Cancer Center Study. Cancer 72:1965-8
Cobleigh, M A; Dowlatshahi, K; Deutsch, T A et al. (1993) Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer. J Clin Oncol 11:474-7

Showing the most recent 10 out of 29 publications